Boyle Scott N 4
4 · C4 Therapeutics, Inc. · Filed Mar 8, 2024
Insider Transaction Report
Form 4
Boyle Scott N
Chief Business Officer
Transactions
- Award
Stock Option (Right to Buy)
2024-03-07+115,000→ 115,000 totalExercise: $19.00Exp: 2032-01-02→ Common Stock (115,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2024-03-07−115,000→ 0 totalExercise: $33.23Exp: 2032-01-02→ Common Stock (115,000 underlying)
Footnotes (2)
- [F1]On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- [F2]25% of the shares underlying this option shall vest and become exercisable on January 3, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.